Pancreatic Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Pancreatic Cancer, including details on symptoms, causes, treatment, information.

Volume 4 (2007), Issue 7 (July)

1. Pancreatic cancer microenvironment.
   Int J Cancer, 121(4): 699-705. [Abstract] [Full-text]
2. Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells.
   Cancer Res, 67(13): 6278-85. [Abstract] [Full-text]
3. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression.
   Cancer Res, 67(13): 6075-82. [Abstract] [Full-text]
4. Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate?
   Gut, 56(8): 1086-90. [Abstract] [Full-text]
5. Expression of snail in pancreatic cancer promotes metastasis and chemoresistance.
   J Surg Res, 141(2): 196-203. [Abstract] [Full-text]
6. S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer.
   Cancer Res, 67(14): 6786-95. [Abstract] [Full-text]
7. Correlating routine cytology, quantitative nuclear morphometry by digital image analysis, and genetic alterations by fluorescence in situ hybridization to assess the sensitivity of cytology for detecting pancreatobiliary tract malignancy.
   Am J Clin Pathol, 128(2): 272-9. [Abstract] [Full-text]
8. Differentiation between pancreaticobiliary and upper gastrointestinal adenocarcinomas: is analysis of cytokeratin 17 expression helpful?
   Am J Clin Pathol, 128(2): 255-9. [Abstract] [Full-text]
9. A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma.
   Cancer Chemother Pharmacol, 60(4): 489-94. [Abstract] [Full-text]
10. DPYD*2A mutation: the most common mutation associated with DPD deficiency.
    Cancer Chemother Pharmacol, 60(4): 503-7. [Abstract] [Full-text]
11. Arterial infusion of 5-fluorouracil combined with concurrent radiotherapy for unresectable pancreatic cancer: results from a pilot study.
    AJR Am J Roentgenol, 189(2): 421-8. [Abstract] [Full-text]
12. Pancreatic cancer and medical history in a population-based case-control study in the San Francisco Bay Area, California.
    Cancer Causes Control, 18(8): 809-19. [Abstract] [Full-text]
13. EUS-guided tissue sampling: comparison of "dual sampling" (Trucut biopsy plus FNA) with "sequential sampling" (Trucut biopsy and then FNA as required).
    Endoscopy, 39(8): 725-30. [Abstract] [Full-text]
14. Loss of WISP-2/CCN5 signaling in human pancreatic cancer: a potential mechanism for epithelial-mesenchymal-transition.
    Cancer Lett, 254(1): 63-70. [Abstract] [Full-text]
15. Cytotoxic action of phorbol esters on human pancreatic cancer cells.
    Int J Cancer, 121(7): 1445-54. [Abstract] [Full-text]

© 2004-2008 Pancreatic Cancer Research Today. All Rights Reserved.